Evaluation of Traditional Medicine Label Compliance Based on CPOTB: Post-Market Surveillance in the Working Area of BPOM Kediri
DOI:
https://doi.org/10.31004/joecy.v6i1.6852Keywords:
traditional medicine, labeling, CPOTB, post market surveillance, BPOM KediriAbstract
Introduction. Post-market surveillance of traditional medicines is an essential regulatory activity to ensure product quality, safety, and the accuracy of information provided to consumers. One critical component of such surveillance is evaluating the compliance of product labels with applicable regulatory requirements.
Aim. This study aimed to assess the conformity of traditional medicine labeling with the implementation of Good Manufacturing Practices for Traditional Medicines (CPOTB) within the working area of BPOM Kediri as part of a risk-based post-market regulatory strategy.
Method. This applied observational study employed a descriptive cross-sectional design. Data were obtained from post-market surveillance activities through sampling of 30 traditional medicine products collected from pharmacies, herbal shops, modern retailers, and traditional markets within the BPOM Kediri jurisdiction during 2023–2025. Label conformity was evaluated using a CPOTB-based checklist in accordance with BPOM Regulation No. 25 of 2021. Data were analyzed descriptively to identify compliance profiles and dominant non-compliance categories.
Result. A total of 30 findings of non-compliance were identified from 30 product samples, demonstrating an increasing trend over the three-year period. The most frequent non-compliance indicators were excessive or misleading claims (30.0%), absence of batch or lot numbers (26.7%), and absence or misuse of marketing authorization numbers (23.3%). These findings indicate potential risks related to consumer protection, product traceability, and regulatory assurance.
Conclusion. Systematic evaluation of traditional medicine labeling through post-market surveillance serves as a strategic regulatory instrument to strengthen oversight, enhance consumer protection, and support effective implementation of CPOTB in Indonesia.
References
Amekyeh, H., Kumadoh, D., Adongo, D. W., Orman, E., Abubakar, S., Dwamena, A., & Aggrey, M. O. (2024). Evaluation of packaging, labels, and some physicochemical properties of herbal antimalarial products on the Ghanaian market. Heliyon, 10(5).
Arafah, A. (2024). Assessment of Medication Labeling Compliance in Outpatient Pharmacy: A Study in Riyadh, Saudi Arabia. Saudi Journal of Clinical Pharmacy, 3(3), 145-153.
Bernardo Gonzaga Figueiredo Faria, R. A. L. (2024). A critical examination of labeling practices in herbal medicinal products. Pharmacy & Pharmacology International Journal, 12(4), 132-136.
BPOM, B. P. O. d. M. R. I. (2021). Peraturan BPOM Nomor 25 Tahun 2021 tentang Penerapan Cara Pembuatan Obat Tradisional yang Baik (CPOTB). Jakarta
BPOM, B. P. O. d. M. R. I. (2024). Peraturan BPOM Nomor 10 Tahun 2024 tentang Pengawasan Obat dan Makanan Berbasis Risiko. Jakarta
Edo, G. I., Obasohan, P., Makia, R. S., Abiola O, T., Umelo, E. C., Jikah, A. N., Yousif, E., Isoje, E. F., Igbuku, U. A., & Opiti, R. A. (2024). The use of quality control parameters in the evaluation of herbal drugs. A review. Discover Medicine, 1(1), 168.
Gambo, A., Gqaleni, N., Lebina, L., & Mathibe, L. J. (2025). Comparative study of the registration procedure of locally manufactured herbal products in selected African countries. Frontiers in Pharmacology, 16, 1695809.
Hossain, C. M., Gera, M., & Ali, K. A. (2022). Current status and challenges of herbal drug development and regulatory aspect: a global perspective. Asian J. Pharm. Clin. Res, 15(2), 31-41.
Jayasinghe, M., Srilal, T. L. I., Prasadi, D. G. P., Madushika, W. S. S., Silva, S. M. D. U., & Subasinghe, S. (2022). Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement. Journal of Pharmaceutical Policy and Practice, 15(1), 13.
Jordan, C. R., Harris, C. M., Miranda, M. I., Kim, D. Y., & Hellberg, R. S. (2023). Labeling compliance and online claims for Ayurvedic herbal supplements on the US market associated with the purported treatment of COVID-19. Food control, 148, 109673.
Kashuri, M., & Yanuar, A. (2025). Regulatory Reform and Policy Mapping in Indonesia’s Traditional Medicine, Health Supplement, and Cosmetic Sectors. Borneo Journal of Pharmacy, 8(4), 408-423.
Pratiwi, R. D., & Rahmawati, E. (2025). Profile of Natural Medicine Registration Document Compliance for Stunting Prevention in 2021–2023. Eruditio: Indonesia Journal of Food and Drug Safety, 5(2), 140-149.
Roziman, N. S. M., Mustafa Din, W., Mahadi, Z., Islahudin, F., & Said, M. M. (2024). Safe use elements of finished herbal products: insights from consumers and practitioners in Malaysia. BMC Complementary Medicine and Therapies, 24(1), 252.
Sharma, J. J. T., Senadheera, S. G., & Samaranayake, N. R. (2024). Compliance of Manufacturer Medicine Labels to the National Regulation in a State Hospital in Sri Lanka. WHO South-East Asia Journal of Public Health, 13(2), 56-59.
Vojvodić, S., Kobiljski, D., Srđenović Čonić, B., & Torović, L. (2025). Landscape of Herbal Food Supplements: Where Do We Stand with Health Claims? Nutrients, 17(9), 1571.
WHO, W. H. O. (2025). Global traditional medicine strategy 2025–2034. World Health Organization. https://www.who.int/teams/who-global-traditional-medicine-centre/traditional-medicine-strategy-2025-2034
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lindawati Setyaningrum, Fenti Indah Nirwana, Dian Reny Agustina

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.







